



• **ANNUAL**
• **REPORT**
• **2021**

Association
for Molecular
Pathology



Contents

- 2** President's Message
- 3** AMP Strategic Plan: Mission Statement, Vision Statement & Core Principles
- 5** 2021 Board of Directors & Committee Chairs
- 6** International Affiliates
- 6** Organizational Relationships
- 7** Public Policy and Advocacy
- 8** Innovation & Improved Patient Care
- 9** Membership and Annual Meeting Overview
- 10** Education Initiatives
- 11** Financial Statement

President's Message



Dear Colleagues, Patients, and Friends,

The ongoing COVID-19 pandemic has demonstrated the critical importance of molecular testing for patient care and public health to a global audience. This year brought welcome hope in the form of vaccines and an expansion of access to testing, but challenges remain as infections or reinfections, supply chain issues, and staffing shortages continue. Nevertheless, I am proud of our community's continual sharing of resources and expertise, and it is an honor to serve as AMP President at this pivotal moment.

AMP members help patients every day by developing and performing advanced molecular testing to provide accurate and timely diagnosis. To help patients understand the essential role molecular professionals play, AMP recently launched "[Molecular Medicine for Patients](#)," a website providing educational resources that were created with input from the patient community. AMP members have also authored numerous communications and publications to share their molecular testing knowledge amidst the pandemic, further cementing our community's reputation as the global experts in all aspects of molecular diagnostics.

While the last two years have limited our opportunities for in-person networking and education, they have brought our community closer in other innovative ways. Starting in 2021, Associate Membership for students, residents, and fellows was made free by our Board of Directors. Volunteers and staff continued to work through a robust Diversity, Equity, and Inclusion effort across all areas of the organization, and successfully recruited a new Working Group of AMP members to spearhead future initiatives. Our volunteer subject matter experts collaborated on more than a dozen practice guidelines in-progress, over 30 position statements and letters in support of AMP's public policy efforts, and nearly 100 hours of online educational content, all accomplished remotely while playing a critical role in the management of a global pandemic. What we accomplished this year, as a community, is really beyond belief.

I wish to thank AMP members for all that they do to serve patients. It has been said many times, but our community is truly needed now more than ever. If you're a molecular professional but not yet a member, I encourage you to join us and experience all that AMP has to offer!

Antonia R. Sepulveda, MD, PhD
George Washington University Department of Pathology

Mission Vision Principles

AMP's strategic plan is dynamic. Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.



**STRATEGIC
PLAN**



**MISSION
STATEMENT**

The Association for Molecular Pathology is a not-for-profit scientific society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care.

Mission Vision Principles

The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care.



- Quality Health Care Through Excellence in Clinical Molecular Testing
- Fostering the Global Community of Molecular Pathology Professionals
- Collaboration to Advance Molecular Pathology
- Advocacy that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- Innovation to Transform Patient Care

2021 Board of Directors & Committee Chairs



President – **Antonia R. Sepulveda, MD, PhD**

President-Elect; Awards and Strategic Opportunities

Committee Chair – **Daniel E. Sabath, MD, PhD**

Past President and Nominating Committee Chair – **Karen Weck, MD**

Secretary-Treasurer and Finance Committee Chair – **Betsy A. Bove, PhD**

Clinical Practice Committee Chair – **Jane Gibson, PhD**

Economic Affairs Committee Chair – **Samuel K. Caughron, MD**

International Affairs Committee – **Rami Mahfouz, MD, MPH**

Membership Affairs Committee Chair – **Shelby Melton, MD**

Professional Relations Committee Chair – **Jordan Laser, MD**

Program Committee Chair – **Laura J. Tafe, MD**

Publication & Communication Committee Chair – **Larissa V. Furtado, MD**

Training & Education Committee Chair – **Nathanael Bailey, MD**

Genetics Subdivision Chair – **Avni Santani, PhD**

Hematopathology Subdivision Chair – **Maria E. Arcila, MD**

Infectious Diseases Subdivision Chair – **Donna M. Wolk, PhD, D(ABMM)**

Informatics Subdivision Chair – **Jason D. Merker, MD, PhD**

Solid Tumors Subdivision Chair – **Lawrence J. Jennings, MD, PhD**

Executive Director – **Mary Steele Williams, MNA, MT(ASCP)SM**

Organizational Relationships

AMP maintains membership in the following organizations:

- Blood PAC
- Cancer Leadership Council (CLC)
- Federation of American Societies for Experimental Biology (FASEB)
- Global Alliance for Genomic Medicine
- Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- Intersociety Pathology Council (IPC)
- Intersociety Council for Pathology Information (ICPI) – Associate Member
- Personalized Medicine Coalition (PMC)

AMP maintains relationships with many professional societies and patient groups. AMP has formal representation in the following groups:

- Representative to ASCO CancerLinQ Steering Committee
- Cooperating Society of the American Board of Pathology (ABP)
- Steering Committee, NIST Genome in A Bottle Consortium
- Associate Member of the Intersociety Council for Pathology Information (ICPI)
- Sponsor of the National Academies Roundtable on Genomics and Precision Health
- Representatives to FNHI Biomarkers Consortium Steering Committees
- Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
- Representative to the CAP Molecular Oncology Committee
- Food and Drug Administration Network of Experts
- Representative to FDA Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD) collaborative
- Representatives to TRUU-Lab initiative

International Affiliates:

- The Hong Kong Society for Molecular Diagnostic Sciences
- The Korean Society for Laboratory Medicine
- The Molecular Pathology Association of India
- The German Society of Pathology
- Brazilian Society of Clinical Pathology and Laboratory Medicine
- The Italian Society of Pathology and Translational Medicine
- American University of Beirut Medical Center
- Middle East Molecular Biology Sources



Advancing Molecular Medicine

Public Policy & Advocacy

In addition to cross-disciplinary advocacy to support the laboratory community and patients we serve during the COVID-19 pandemic, AMP pursued a wide range of economic and policy initiatives in 2021, including:

- Publishing of “Analysis of Effort in Molecular Test Interpretation,” breaking down the growing demand (yet declining reimbursement) for molecular test data analysis, interpretation and reporting
- Hosting a virtual Capitol Hill Day to educate lawmakers on the value of laboratory developed testing procedures (LDPs)
- Issuing recommendations on variant data sharing by clinical laboratories & public repositories
- Launching new infectious diseases resources on our “Molecular Medicine for Patients” microsite, outreach.amp.org

For a full overview of AMP’s Advocacy efforts, please visit our Position Statements & Letters webpage.

www.amp.org/advocates

Innovation & Improved Patient Care



AMP published one clinical practice guideline in 2021 and supported numerous efforts to provide member expertise during the pandemic and advance other areas of patient care. As just one example, AMP and the Infectious Diseases Society of America issued a joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making in March.

AMP volunteers are also working on more than a dozen guidelines in progress and serving as external representatives on more than 30 projects with other scientific societies and institutions.

www.amp.org/innovates

Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy.

September; 23 (9): 1047-1064

Membership and Annual Meeting Overview

Total AMP membership grew for the 15th year in a row in 2021, surpassing **2,601 members** for the first time. While individual membership associations across all industries saw declines, AMP was pleased to see membership growth, and to maintain a presence in **57 countries**.

2,601

MEMBERS

57

COUNTRIES

1,166

PHYSICIANS

856

DOCTORAL SCIENTISTS

579

TECHNOLOGISTS,
TRAINEES &
OTHER

The AMP Europe 2021 Congress was hosted virtually on June 14-18, bringing together molecular professionals from around the world. The continuing COVID-19 pandemic made it impossible to hold our 2021 Annual Meeting & Expo in Philadelphia in November.

Instead, AMP was able offer a number of virtual Corporate Workshops, select scientific presentations and exciting networking opportunities during the week of the intended meeting. The recordings from the full scientific programs, as well as recorded corporate workshops, are now available.

We look forward to welcoming attendees and exhibitors back to in-person events as soon as safely feasible.

Education Initiatives

AMP's digital education initiatives continued to be enhanced in 2021, at a time when they were needed more than ever due to continued social distancing. Our Molecular Genetic Pathology course and postponed AMP Europe meeting were both successfully held virtually. AMP also pivoted many offerings planned for the annual meeting to the 2021 Digital Experience when it became apparent that hosting the planned in-person events was no longer feasible.

New in 2021, AMP launched its **"Molecular in a Minute"** series and an 8-part webinar series devoted to liquid biopsy. It also expanded its offerings of certificate programs, on-demand webinars, flashcards, and **"Molecular in My Pocket"** reference cards. To learn more, visit educate.amp.org.

EMERGING
AND EVOLVING
BIOMARKERS

LABORATORY
MANAGEMENT
CERTIFICATE
PROGRAM

NGS 101
V2.0

COVID-19
RESOURCES



Financial Statement

STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2021	2020	2019
Advocacy	\$ (505,376)	\$ (480,376)	\$ (612,500)
Communications & Outreach	\$ (179,004)	\$ (140,059)	\$ (149,155)
Education	\$ 248,073	\$ 370,854	\$ 1,832,607
Innovation & Improved Patient Care	\$ (182,833)	\$ (369,395)	\$ (290,091)
Membership & Management Services	\$ 296,469	\$ 140,944	\$ (76,388)
EXCESS REVENUE OVER EXPENSES	\$ (322,671)	\$ 478,031	\$ 704,474



AMP

ASSOCIATION
FOR MOLECULAR
PATHOLOGY

6120 Executive Boulevard
Suite 700
Rockville, Maryland, 20852

amp.org